window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : May 13, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Featured

  • Clinical & Regulatory,Drug Discovery & Development

    Japan pushes AI clinical trials agenda as global pharma leaders gather in Tokyo

    Japan’s push to modernise clinical research through artificial intelligence and [...]

    May 7, 2026
  • Uncategorised

    Longitude Prize on ALS awards £2m to AI drug discovery teams

    The Longitude Prize on ALS has awarded £2 million to [...]

    May 7, 2026
  • Medical devices

    University of Huddersfield wins award for 3D wound training models

    Researchers at the University of Huddersfield have won two prizes [...]

    May 7, 2026
  • Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Intellia reports first positive Phase 3 in vivo CRISPR data in hereditary angioedema

    Intellia Therapeutics has reported positive Phase 3 results for lonvoguran [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    NETRIS Pharma Nature publishes pancreatic cancer Phase 1b data showing NP137 survival and surgery gains

    Nature publishes Phase 1b data showing NETRIS Pharma’s NP137 improves [...]

    May 5, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Alto starts Phase 2b ALTO-207 trial in treatment-resistant depression

    Alto Neuroscience has started a Phase 2b trial of ALTO-207 [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    ARTCLINE completes enrolment in septic shock trial for ARTICE therapy

    ARTCLINE has completed patient enrolment in a 142-patient randomized study [...]

    May 5, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Regeneron enters radiopharmaceuticals through multi-programme collaboration with Telix in oncology expansion

    Regeneron Pharmaceuticals has entered the radiopharmaceuticals field through a multi-programme [...]

    May 5, 2026
  • Drug Discovery & Development,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics

    Pharma firms localise GLP-1 supply chains as shortages and geopolitical risks grow

    Drugmakers are regionalising GLP-1 manufacturing as demand surges, shortages persist [...]

    May 5, 2026
  • Clinical & Regulatory,Therapeutic Areas

    Kainova Therapeutics doses first patient in Europe in phase 1/2 anti-CCR8 antibody trial

    Kainova Therapeutics has dosed the first patient in Europe in [...]

    May 5, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Trelleborg gains ISO certification for Costa Rica medtech plant
    Categories: Clinical & Regulatory, Manufacturing & Supply Chain, Medical devices
  • Merck launches bio-based HPLC solvents for pharma labs
    Categories: Drug Discovery & Development, Manufacturing & Supply Chain
  • Alto starts Phase 2b ALTO-207 trial in treatment-resistant depression
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top